NSE 神經(jīng)元特異性烯醇化酶

廣州健侖生物科技有限公司

NSE是一種胞漿內(nèi)蛋白，在哺乳動物中烯醇化酶是二聚體，有α、β、γ3個(gè)亞基，γ亞基主要達(dá)于神經(jīng)元細(xì)胞、某些神經(jīng)內(nèi)分泌細(xì)胞及其腫瘤，在陽性細(xì)胞中表現(xiàn)為彌漫性胞漿染色。此抗體可以特異性識別46kDa的NSE，可用于神經(jīng)內(nèi)分泌腫瘤的研究。由于平滑肌、肌上皮細(xì)胞、腎小管細(xì)胞、淋巴細(xì)胞等也可表達(dá)NSE，所以此抗體應(yīng)注意和其它抗體聯(lián)合應(yīng)用。

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢

NSE 神經(jīng)元特異性烯醇化酶

【產(chǎn)品介紹】

細(xì)胞定位：細(xì)胞漿

克隆號：MRQ-55

同型：IgG

適用組織：石蠟/冰凍

陽性對照：胰腺

抗原修復(fù)：熱修復(fù)（EDTA）

抗體孵育時(shí)間：30-60min

NSE

想了解更多的產(chǎn)品及服務(wù)請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】     歐

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-103室

萊斯大學(xué)和得克薩斯大學(xué)MD安德森癌癥中心一項(xiàng)新的研究顯示了卵巢癌如何利用腹部組織來源的一種特定類型的成體干細(xì)胞來推動其增長。這項(xiàng)研究在線發(fā)表在上周的Cancer Research雜志上，該研究提出了一種新的治療方式來針對侵襲性卵巢癌，即通過破壞促使癌細(xì)胞茁壯成長的代謝過程。
這種特定類型干細(xì)胞被稱為大網(wǎng)膜脂肪基質(zhì)細(xì)胞或O-ASCs，已經(jīng)與卵巢腫瘤的增殖，遷移和耐藥性有關(guān)，但此類干細(xì)胞的確切作用是未知的，研究論文*研究員Rice's Deepak Nagrath說：我們發(fā)現(xiàn)，O-ASCs供給癌細(xì)胞產(chǎn)生一氧化氮所需要的代謝物，一氧化氮是已知增加血流量的重要信號分子。癌癥研究人員在80年前發(fā)現(xiàn)癌細(xì)胞與正常細(xì)胞之間的代謝差異。幾十年來，科學(xué)家相信“Warburg效應(yīng)”適用于所有的癌癥，但Nagrath實(shí)驗(yàn)室研究和其他人已經(jīng)發(fā)現(xiàn)，每一種類型的癌癥都有自己的代謝特征。
例如，在五月發(fā)表的一項(xiàng)研究中，Nagrath及其同事發(fā)現(xiàn)高度侵襲性卵巢癌細(xì)胞是谷氨酰胺依賴性的，在實(shí)驗(yàn)室中剝奪細(xì)胞谷氨酰胺的外部來源，一些實(shí)驗(yàn)性藥物能有效殺死晚期卵巢癌細(xì)胞。

NSE is a cytoplasmic protein, enolase in mammals is a dimer, α, β, γ 3 subunits, γ subunit mainly in neurons, some neuroendocrine cells and their tumors, In the positive cells showed diffuse cytoplasmic staining. This antibody can specifically recognize 46kDa NSE and can be used in the study of neuroendocrine tumors. As smooth muscle, myoepithelial cells, tubular cells, lymphocytes, etc. can also express NSE, so this antibody should be noted that combined with other antibodies.

A new study by Rice University and the MD Anderson Cancer Center at the University of Texas shows how ovarian cancer uses a particular type of adult stem cell from abdominal tissue to drive its growth. The study, published online last week in the journal Cancer Research, suggests a new treatment for aggressive ovarian cancer, the metabolic process that promotes the robust growth of cancer cells through destruction.
This particular type of stem cell, known as omental adipose-derived stromal cells or O-ASCs, has been implicated in the proliferation, migration and drug resistance of ovarian tumors, but the exact role of such stem cells is unknown, and Rice's Deepak, lead researcher in the research paper Nagrath says: We found that O-ASCs supply the metabolites needed by cancer cells to produce nitric oxide, an important signaling molecule known to increase blood flow. Cancer researchers discovered the metabolic difference between cancer cells and normal cells 80 years ago. For decades, scientists believe the "Warburg effect" applies to all cancers, but Nagrath laboratory research and others have found that each type of cancer has its own metabolic profile.
In a study published in May, for example, Nagrath and colleagues found that highly aggressive ovarian cancer cells are glutamine-dependent, deprived of an external source of cellular glutamine in the laboratory and that some experimental drugs are effective Kill advanced ovarian cancer cells.